Allergy Therapuetics Valuation Multiples

Allergy Therapuetics Overview

About Allergy Therapuetics

Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).

Founded

2004

HQ

Employees

602

Website

allergytherapeutics.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $83M

EBITDA: ($39M)

EV

$922M

Valuation Multiples

Multiples.vc

Start free trial

Allergy Therapuetics Financials

Allergy Therapuetics reported last 12-month revenue of $83M and negative EBITDA of ($39M).

In the same LTM period, Allergy Therapuetics generated $47M in gross profit, ($39M) in EBITDA losses, and had net loss of ($64M).

Allergy Therapuetics P&L

In the most recent fiscal year, Allergy Therapuetics reported revenue of $74M and EBITDA of ($33M).

Allergy Therapuetics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Allergy Therapuetics Stock Performance

Allergy Therapuetics has current market cap of $899M, and enterprise value of $922M.

Allergy Therapuetics' stock price is $0.14.

Allergy Therapuetics Valuation Multiples

Allergy Therapuetics trades at 11.1x EV/Revenue multiple, and (23.6x) EV/EBITDA.

Allergy Therapuetics Financial Valuation Multiples

As of April 18, 2026, Allergy Therapuetics has market cap of $899M and EV of $922M.

Equity research analysts estimate Allergy Therapuetics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Allergy Therapuetics has a P/E ratio of (14.0x).

Allergy Therapuetics Margins & Growth Rates

Allergy Therapuetics' revenue in the last 12 month grew by 3%.

Allergy Therapuetics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Allergy Therapuetics' rule of 40 is (41%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Allergy Therapuetics' rule of X is (30%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Allergy Therapuetics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Allergy Therapuetics M&A Activity

Allergy Therapuetics acquired XXX companies to date.

Last acquisition by Allergy Therapuetics was on XXXXXXXX, XXXXX. Allergy Therapuetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Allergy Therapuetics Investment Activity

Allergy Therapuetics invested in XXX companies to date.

Allergy Therapuetics made its latest investment on XXXXXXXX, XXXXX. Allergy Therapuetics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).